CoChat

Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes

Sjöström, C David, Johansson, Peter, Ptaszynska, Agata, List, James, Johnsson, Eva · 2015 · Diabetes and Vascular Disease Research

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

The effect of dapagliflozin on blood pressure was evaluated in non-hypertensive (<140 mm Hg) and hypertensive (⩾140 mm Hg) patients with type 2 diabetes mellitus. Data were pooled from 13 placebo-controlled studies. Patients received dapagliflozin 10 mg/day ( n = 2360) or placebo ( n = 2295) for up to 24 weeks. Dapagliflozin was associated with placebo-subtracted changes from baseline in systolic and diastolic blood pressures of −3.6 and −1.2 mm Hg, respectively, in hypertensive patients and −2.6 and −1.2 mm Hg, respectively, in non-hypertensive patients. At 24 weeks, a similar proportion of patients experienced measured orthostatic reactions with dapagliflozin versus placebo in hypertensive (6.1% and 6.6%, respectively) and non-hypertensive (4.0% and 4.2%) patients. No clinically relevant difference was observed between dapagliflozin and placebo in heart rate. In conclusion, dapagliflozin 10 mg induces a modest reduction in blood pressure compared with placebo in patients with diabetes with a low risk of orthostatic reactions, regardless of baseline blood pressure.

Overview

Integrity signals

Registry

Crossref · 10.1177/1479164115585298

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 2

  1. Sjostrom CD, 2013, Diabetolgia, 56, S81
  2. Dornfeld LP, 1985, Int J Obes, 9, 381

Cited by

See all 103

Metadata

Authors
Sjöström, C. D., Johansson, P., Ptaszynska, A., List, J., & Johnsson, E.
Affiliations
  • AstraZeneca (Sweden) (SE)
  • Bristol-Myers Squibb (United States) (US)
Venue
Diabetes and Vascular Disease Research
Published
2015-05-25
Volume
12
Issue
5
Pages
352-358
ISSN
  • 1479-1641 (ISSN-L)
  • 1752-8984
OpenAlex
W2154525074
Cited by
97
References
25
Citations by year
2026: 2 · 2025: 3 · 2024: 10 · 2023: 6 · 2022: 13 · 2021: 12 · 2020: 9 · 2019: 12 · 2018: 5 · 2017: 7 · 2016: 11 · 2015: 5
FWCI
8.09
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Diabetes and Vascular Disease Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
dapagliflozin, blood pressure reduction, hypertension, type 2 diabetes, SGLT2 inhibitors, orthostatic reaction, heart rate, antihypertensive effect
MeSH terms
Adult, Aged, Aged, 80 and over, Benzhydryl Compounds, Blood Pressure, Blood Pressure Determination, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. https://app.cochat.ai/papers/10.1177/1479164115585298
The paper
Sjöström, C. D., Johansson, P., Ptaszynska, A., List, J., & Johnsson, E. (2015). Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diabetes and Vascular Disease Research. https://doi.org/10.1177/1479164115585298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.